CASI Pharmaceuticals, Inc. (CASI)
NASDAQ: CASI · Real-Time Price · USD
1.020
+0.030 (3.02%)
At close: Jan 30, 2026, 4:00 PM EST
0.9601
-0.0600 (-5.87%)
After-hours: Jan 30, 2026, 4:15 PM EST
CASI Pharmaceuticals Employees
CASI Pharmaceuticals had 233 employees as of December 31, 2024. The number of employees increased by 57 or 32.39% compared to the previous year.
Employees
233
Change (1Y)
57
Growth (1Y)
32.39%
Revenue / Employee
$115,219
Profits / Employee
-$211,953
Market Cap
20.96M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 233 | 57 | 32.39% | 233 | 0 |
| Dec 31, 2023 | 176 | -48 | -21.43% | 176 | 0 |
| Dec 31, 2022 | 224 | 48 | 27.27% | 224 | 0 |
| Dec 31, 2021 | 176 | 32 | 22.22% | 176 | 0 |
| Dec 31, 2020 | 144 | 19 | 15.20% | 144 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 61 |
| Lunai Bioworks | 29 |
| IN8bio | 17 |
| Quantum BioPharma | 17 |
| Neuphoria Therapeutics | 8 |
| ProMIS Neurosciences | 8 |
| Allarity Therapeutics | 7 |
| Traws Pharma | 7 |
CASI News
- 15 days ago - CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR) - Accesswire
- 18 days ago - CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia - Accesswire
- 5 weeks ago - CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements - Accesswire
- 7 weeks ago - CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing - Accesswire
- 7 weeks ago - CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting - Accesswire
- 2 months ago - CASI Pharmaceuticals Announces Changes in Board Governance - Accesswire
- 2 months ago - CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results - Accesswire
- 2 months ago - CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ - Accesswire